PMID- 29151359
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20220603
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 2
DP  - 2018 Jan 11
TI  - Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
PG  - 113-125
LID - 10.1056/NEJMoa1713137 [doi]
AB  - BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal 
      growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively 
      inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We 
      compared osimertinib with standard EGFR-TKIs in patients with previously 
      untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). 
      METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients 
      with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) 
      advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg 
      once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or 
      erlotinib at a dose of 150 mg once daily). The primary end point was 
      investigator-assessed progression-free survival. RESULTS: The median 
      progression-free survival was significantly longer with osimertinib than with 
      standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease 
      progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). 
      The objective response rate was similar in the two groups: 80% with osimertinib 
      and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24). 
      The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with 
      osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data 
      on overall survival were immature at the interim analysis (25% maturity). The 
      survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% 
      (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 
      0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events 
      of grade 3 or higher were less frequent with osimertinib than with standard 
      EGFR-TKIs (34% vs. 45%). CONCLUSIONS: Osimertinib showed efficacy superior to 
      that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive 
      advanced NSCLC, with a similar safety profile and lower rates of serious adverse 
      events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).
FAU - Soria, Jean-Charles
AU  - Soria JC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Ohe, Yuichiro
AU  - Ohe Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Vansteenkiste, Johan
AU  - Vansteenkiste J
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Reungwetwattana, Thanyanan
AU  - Reungwetwattana T
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Chewaskulyong, Busyamas
AU  - Chewaskulyong B
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Lee, Ki Hyeong
AU  - Lee KH
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Dechaphunkul, Arunee
AU  - Dechaphunkul A
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Imamura, Fumio
AU  - Imamura F
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Nogami, Naoyuki
AU  - Nogami N
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Kurata, Takayasu
AU  - Kurata T
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Okamoto, Isamu
AU  - Okamoto I
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Zhou, Caicun
AU  - Zhou C
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Cho, Byoung Chul
AU  - Cho BC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Cheng, Ying
AU  - Cheng Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Cho, Eun Kyung
AU  - Cho EK
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Voon, Pei Jye
AU  - Voon PJ
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Planchard, David
AU  - Planchard D
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Su, Wu-Chou
AU  - Su WC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Gray, Jhanelle E
AU  - Gray JE
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Lee, Siow-Ming
AU  - Lee SM
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Hodge, Rachel
AU  - Hodge R
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Marotti, Marcelo
AU  - Marotti M
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Rukazenkov, Yuri
AU  - Rukazenkov Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
FAU - Ramalingam, Suresh S
AU  - Ramalingam SS
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France 
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center 
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research 
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu 
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, 
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, 
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the 
      Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the 
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of 
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei 
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology 
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical 
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji 
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun 
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); 
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of 
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
      (J.E.G.); the Department of Oncology, University College London Hospitals 
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of 
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all 
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer 
      Institute, Atlanta (S.S.R.).
CN  - FLAURA Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02296125
SI  - ClinicalTrials.gov/NCT02296125
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171118
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - S65743JHBS (Gefitinib)
SB  - IM
CIN - N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580. PMID: 
      29320658
CIN - N Engl J Med. 2018 Mar 29;378(13):1261. doi: 10.1056/NEJMc1801669. PMID: 29595922
CIN - N Engl J Med. 2018 Mar 29;378(13):1261-2. doi: 10.1056/NEJMc1801669. PMID: 
      29595923
CIN - N Engl J Med. 2018 Mar 29;378(13):1262. doi: 10.1056/NEJMc1801669. PMID: 29595924
CIN - Ann Transl Med. 2018 Feb;6(3):57. doi: 10.21037/atm.2017.12.13. PMID: 29611546
CIN - Ann Transl Med. 2018 Feb;6(3):61. doi: 10.21037/atm.2017.12.27. PMID: 29611548
CIN - J Thorac Dis. 2018 Mar;10(3):1265-1268. doi: 10.21037/jtd.2018.03.28. PMID: 
      29708166
CIN - Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 
      10.21037/tlcr.2018.03.19. PMID: 29782558
CIN - Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S127-S130. doi: 
      10.21037/tlcr.2018.03.06. PMID: 29782562
CIN - J Thorac Dis. 2018 Apr;10(Suppl 9):S1076-S1080. doi: 10.21037/jtd.2018.03.92. 
      PMID: 29849216
CIN - Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S187-S190. doi: 
      10.21037/tlcr.2018.04.16. PMID: 30393597
CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S3837-S3839. doi: 10.21037/jtd.2018.09.52. 
      PMID: 30631492
MH  - Acrylamides
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aniline Compounds
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - ErbB Receptors/*genetics
MH  - Erlotinib Hydrochloride/therapeutic use
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy/genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinazolines/therapeutic use
MH  - Survival Rate
FIR - Boyer, Michael
IR  - Boyer M
FIR - Lee, Chee
IR  - Lee C
FIR - Hughes, Brett
IR  - Hughes B
FIR - O'Byrne, Kenneth
IR  - O'Byrne K
FIR - Briggs, Peter
IR  - Briggs P
FIR - Milward, Michael
IR  - Milward M
FIR - John, Thomas
IR  - John T
FIR - Demedts, Ingel
IR  - Demedts I
FIR - Bustin, Frederique
IR  - Bustin F
FIR - Barrios, Carlos Henrique
IR  - Barrios CH
FIR - Timcheva, Constanta
IR  - Timcheva C
FIR - Butts, Charles
IR  - Butts C
FIR - Goss, Glenwood
IR  - Goss G
FIR - Juergens, Rosalyn
IR  - Juergens R
FIR - Leighl, Natasha
IR  - Leighl N
FIR - Cheng, Susanna
IR  - Cheng S
FIR - Burkes, Ronald
IR  - Burkes R
FIR - Zhang, Helong
IR  - Zhang H
FIR - Shu, Yongqian
IR  - Shu Y
FIR - Zhou, Qing
IR  - Zhou Q
FIR - Li, Wei
IR  - Li W
FIR - Feng, Guosheng
IR  - Feng G
FIR - He, Yong
IR  - He Y
FIR - Wang, Buhai
IR  - Wang B
FIR - Gao, Hongjun
IR  - Gao H
FIR - Nan, Kejun
IR  - Nan K
FIR - Zhou, Xiangdong
IR  - Zhou X
FIR - Fan, Yun
IR  - Fan Y
FIR - Hunag, Jian an
IR  - Hunag JA
FIR - Hu, Yi
IR  - Hu Y
FIR - Liu, Yun-Peng
IR  - Liu YP
FIR - Liu, Chunling
IR  - Liu C
FIR - Zhang, Yiping
IR  - Zhang Y
FIR - Zhu, Bo
IR  - Zhu B
FIR - Bartek, Tomas
IR  - Bartek T
FIR - Monnet, Isabelle
IR  - Monnet I
FIR - El Kouri, Claude
IR  - El Kouri C
FIR - Perol, Maurice
IR  - Perol M
FIR - Berard, Henri
IR  - Berard H
FIR - Madelaine, Jeannick
IR  - Madelaine J
FIR - von Pawel, Joachim
IR  - von Pawel J
FIR - Grohe, Christian
IR  - Grohe C
FIR - Bohnet, Sabine
IR  - Bohnet S
FIR - Bischoff, Helge
IR  - Bischoff H
FIR - zum Buschenfelde, Christian Meyer
IR  - zum Buschenfelde CM
FIR - Ruckert, Anja
IR  - Ruckert A
FIR - Urban, Lazlo
IR  - Urban L
FIR - Papi-Szekely, Zsolt
IR  - Papi-Szekely Z
FIR - Csanky, Eszter
IR  - Csanky E
FIR - Bocskei, Csaba
IR  - Bocskei C
FIR - Tehenes, Sandor
IR  - Tehenes S
FIR - Gottfried, Maya
IR  - Gottfried M
FIR - Bar, Jair
IR  - Bar J
FIR - Peled, Nir
IR  - Peled N
FIR - Wollner, Mirjana
IR  - Wollner M
FIR - Bertolini, Alessandro
IR  - Bertolini A
FIR - Ardizzoia, Antonio
IR  - Ardizzoia A
FIR - Accettura, Caterina
IR  - Accettura C
FIR - Mitella, Michele
IR  - Mitella M
FIR - Passalacqua, Rodolfo
IR  - Passalacqua R
FIR - Novello, Silvia
IR  - Novello S
FIR - Roila, Fausto
IR  - Roila F
FIR - Tiseo, Marcello
IR  - Tiseo M
FIR - Sekine, Akimasa
IR  - Sekine A
FIR - Takahashi, Toshiaki
IR  - Takahashi T
FIR - Kasahara, Kazuo
IR  - Kasahara K
FIR - Yoh, Kiyotaka
IR  - Yoh K
FIR - Sugawara, Shunichi
IR  - Sugawara S
FIR - Kobayashi, Nobuaki
IR  - Kobayashi N
FIR - Shimokawa, Tsuneo
IR  - Shimokawa T
FIR - Okuda, Chiyuki
IR  - Okuda C
FIR - Fukuhara, Tatsuo
IR  - Fukuhara T
FIR - Sata, Masafumi
IR  - Sata M
FIR - Nagakawa, Kazuhiko
IR  - Nagakawa K
FIR - Atagi, Shinji
IR  - Atagi S
FIR - Nakahara, Yoshiro
IR  - Nakahara Y
FIR - Lee, Jong-Seok
IR  - Lee JS
FIR - Lee, Kye Young
IR  - Lee KY
FIR - Shin, Sang Won
IR  - Shin SW
FIR - Kang, Jin-Hyoung
IR  - Kang JH
FIR - How, Soon Hin
IR  - How SH
FIR - Pang, Yong Kek
IR  - Pang YK
FIR - Osorio-Sanchez, Jemela Anne
IR  - Osorio-Sanchez JA
FIR - Ladrera, Guia Elena Imelda
IR  - Ladrera GEI
FIR - Serwatowski, Piotr
IR  - Serwatowski P
FIR - Szczesna, Aleksandra
IR  - Szczesna A
FIR - Zajda, Katarzyna
IR  - Zajda K
FIR - Ramlau, Rodryg
IR  - Ramlau R
FIR - Sawka, Dariusz
IR  - Sawka D
FIR - Encarnacao Teixeira, Maria
IR  - Encarnacao Teixeira M
FIR - Almodovar, Teresa
IR  - Almodovar T
FIR - Soares, Marta
IR  - Soares M
FIR - Almeida, Amelia
IR  - Almeida A
FIR - Barroso, Ana
IR  - Barroso A
FIR - Schenker, Michael
IR  - Schenker M
FIR - Girgorescu, Alexandru Calin
IR  - Girgorescu AC
FIR - Iorga, Polixenia
IR  - Iorga P
FIR - Orlov, Sergey
IR  - Orlov S
FIR - Karaseva, Nina
IR  - Karaseva N
FIR - Moiseenko, Vladimir
IR  - Moiseenko V
FIR - Garcia Campelo, Rosario
IR  - Garcia Campelo R
FIR - Isla Casado, Maria Dolores
IR  - Isla Casado MD
FIR - Cobo Dols, Manuel
IR  - Cobo Dols M
FIR - Nadal, Ernest
IR  - Nadal E
FIR - Campayo Guillaumes, Marc
IR  - Campayo Guillaumes M
FIR - Gonzalez Larriba, Jose Luis
IR  - Gonzalez Larriba JL
FIR - Majem Tarruella, Margarita
IR  - Majem Tarruella M
FIR - Vazquez Estevez, Sergio
IR  - Vazquez Estevez S
FIR - Fuentes Pradera, Jose
IR  - Fuentes Pradera J
FIR - Marquez Medina, Diego
IR  - Marquez Medina D
FIR - Vikstrom, Anders
IR  - Vikstrom A
FIR - Gautschi, Oliver
IR  - Gautschi O
FIR - Britschgi, Christian
IR  - Britschgi C
FIR - Mueller, Andreas
IR  - Mueller A
FIR - Tsai, Ying-Huang
IR  - Tsai YH
FIR - Wu, Ming-Fang
IR  - Wu MF
FIR - Yang, Cheng-Ta
IR  - Yang CT
FIR - Lin, Meng Chih
IR  - Lin MC
FIR - Chen, Chao-Hsun
IR  - Chen CH
FIR - Srimuninnimit, Vichien
IR  - Srimuninnimit V
FIR - Laohavinij, Sudsawat
IR  - Laohavinij S
FIR - Sriuranpong, Virote
IR  - Sriuranpong V
FIR - Yildiz, Ramazan
IR  - Yildiz R
FIR - Bondarenko, Igor
IR  - Bondarenko I
FIR - Vynnychenko, Ihor
IR  - Vynnychenko I
FIR - Adamchuk, Hryhoriy
IR  - Adamchuk H
FIR - Shparyk, Yaroslav
IR  - Shparyk Y
FIR - Price, Allan
IR  - Price A
FIR - Summers, Yvonne
IR  - Summers Y
FIR - Shah, Riyaz
IR  - Shah R
FIR - Dragnev, Konstantin
IR  - Dragnev K
FIR - Maniam, Ajit
IR  - Maniam A
FIR - McCune, Steven
IR  - McCune S
FIR - Ruiz, Jimmy
IR  - Ruiz J
FIR - Janne, Pasi
IR  - Janne P
FIR - Feinstein, Trevor
IR  - Feinstein T
FIR - Hamm, John
IR  - Hamm J
FIR - Anderson, Ian
IR  - Anderson I
FIR - Khan, Farrah
IR  - Khan F
FIR - Boccia, Ralph
IR  - Boccia R
FIR - Tran, Ngoc
IR  - Tran N
FIR - Nguyen, Nhung
IR  - Nguyen N
EDAT- 2017/11/21 06:00
MHDA- 2018/01/19 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - 10.1056/NEJMoa1713137 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 
      Nov 18.